> top > docs > PMC:7187660 > annotations

PMC:7187660 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 59-67 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 135-143 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 571-579 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 672-680 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T5 683-692 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T6 910-918 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T7 1208-1230 Disease denotes cardiovascular disease http://purl.obolibrary.org/obo/MONDO_0004995
T8 1274-1286 Disease denotes hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T9 1330-1338 Disease denotes diabetes http://purl.obolibrary.org/obo/MONDO_0005015
T10 1382-1401 Disease denotes respiratory disease http://purl.obolibrary.org/obo/MONDO_0005087
T11 1552-1560 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T12 1627-1635 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 2467-2479 Disease denotes Hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T14 2548-2556 Disease denotes Diabetes http://purl.obolibrary.org/obo/MONDO_0005015
T15 2622-2644 Disease denotes Cardiovascular disease http://purl.obolibrary.org/obo/MONDO_0004995
T16 2709-2728 Disease denotes Respiratory disease http://purl.obolibrary.org/obo/MONDO_0005087
T17 2791-2797 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992
T18 3130-3138 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 153-156 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T2 162-163 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 428-430 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T4 613-614 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T5 740-742 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T6 1070-1074 http://purl.obolibrary.org/obo/UBERON_0003101 denotes male
T7 1070-1074 http://www.ebi.ac.uk/efo/EFO_0000970 denotes male
T8 1122-1128 http://purl.obolibrary.org/obo/UBERON_0003100 denotes female
T9 1811-1814 http://purl.obolibrary.org/obo/CLO_0001414 denotes 548
T10 1886-1888 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T11 2316-2320 http://purl.obolibrary.org/obo/UBERON_0003101 denotes Male
T12 2316-2320 http://www.ebi.ac.uk/efo/EFO_0000970 denotes Male
T13 2393-2399 http://purl.obolibrary.org/obo/UBERON_0003100 denotes Female
T14 2729-2732 http://purl.obolibrary.org/obo/CLO_0001405 denotes 511
T15 2918-2921 http://purl.obolibrary.org/obo/CLO_0001445 denotes 617
T16 3027-3028 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T17 3042-3043 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T18 3166-3170 http://purl.obolibrary.org/obo/UBERON_0003101 denotes male
T19 3166-3170 http://www.ebi.ac.uk/efo/EFO_0000970 denotes male
T20 3184-3185 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T21 3228-3234 http://purl.obolibrary.org/obo/UBERON_0003100 denotes female
T22 3305-3306 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T23 3565-3566 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T24 3665-3669 http://purl.obolibrary.org/obo/UBERON_0003101 denotes male
T25 3665-3669 http://www.ebi.ac.uk/efo/EFO_0000970 denotes male
T26 4016-4018 http://purl.obolibrary.org/obo/CLO_0050475 denotes MY
T27 4023-4025 http://purl.obolibrary.org/obo/CLO_0009645 denotes XC
T28 4023-4025 http://purl.obolibrary.org/obo/CLO_0050824 denotes XC

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 1070-1074 Chemical denotes male http://purl.obolibrary.org/obo/CHEBI_30780
T2 1139-1141 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T3 1232-1234 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T4 1340-1342 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T5 1403-1405 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T6 1458-1460 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T7 1732-1734 Chemical denotes RR http://purl.obolibrary.org/obo/CHEBI_73811
T8 2892-2897 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T9 2943-2948 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T10 2978-2983 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T11 3166-3170 Chemical denotes male http://purl.obolibrary.org/obo/CHEBI_30780
T12 3665-3669 Chemical denotes male http://purl.obolibrary.org/obo/CHEBI_30780
T13 3958-3960 Chemical denotes GD http://purl.obolibrary.org/obo/CHEBI_73804

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-67 Sentence denotes Clinical determinants for fatality of 44,672 patients with COVID-19
T2 69-229 Sentence denotes Using meta-analysis to explore clinical determinants for death of COVID-19 patients has been a problem due to insufficient sample size and overlapped cases [1].
T3 230-503 Sentence denotes In the study, we re-analyzed the largest confirmed case series reported publicly by the Chinese center for disease control and prevention (44,672 laboratory confirmed cases updated through February 11, 2020, [2]), to explore the clinical risk factors associated with death.
T4 504-606 Sentence denotes The basic characteristics between survivors and non-survivors with COVID-19 were presented in Table 1.
T5 607-776 Sentence denotes Among a total of 44,672 patients with laboratory confirmation of SARS-CoV-2 infection, 1023 (2.3%) patients were dead as of February 11, 2020, the last day of follow-up.
T6 777-891 Sentence denotes The fatality rate was increasing with ages and even up to 14.8% in patients aged above 80 years old (see Fig. 1a).
T7 892-1039 Sentence denotes The prevalence of COVID-19 between men and women was pretty close (51.4% vs. 48.6%), which is different from previous report (58.1% vs. 41.9%) [3].
T8 1040-1194 Sentence denotes Notably, the fatality rate of male patients was significantly higher than that of female patients (RR = 1.67, 95%CI = 1.47–1.89, p < 0.001) (see Fig. 1b).
T9 1195-1561 Sentence denotes Furthermore, cardiovascular disease (RR = 6.75, 95%CI = 5.40–8.43, p < 0.001), hypertension (HR = 4.48, 95%CI = 3.69–5.45, p < 0.001), diabetes (RR = 4.43, 95%CI = 3.49–5.61, p < 0.001), respiratory disease (RR = 3.43, 95%CI = 2.42–4.87, p < 0.001), and cancers (RR = 2.926, 95%CI = 1.34–6.41, p = 0.006) were the risk factors for fatality of patients with COVID-19.
T10 1562-1635 Sentence denotes Table 1 Characteristics between survivors and non-survivors with COVID-19
T11 1636-1744 Sentence denotes Characteristics Total (n = 44,672) Non-survivors (n = 1023) Survivors (n = 43,649) Fatality (%) RR (95%CI) p
T12 1745-1755 Sentence denotes Age, n (%)
T13 1756-1785 Sentence denotes  0– 416 (0.9%) 0 416 (0.9%) 0
T14 1786-1825 Sentence denotes  10– 549 (1.2%) 1 (0.1%) 548 (1.3%) 0.2
T15 1826-1867 Sentence denotes  20– 3619 (8.1%) 7 (0.7%) 3612 (8.3%) 0.2
T16 1868-1912 Sentence denotes  30– 7600 (17.0%) 18 (1.8%) 7582 (17.4%) 0.2
T17 1913-1957 Sentence denotes  40– 8571 (19.2%) 38 (3.7%) 8533 (19.5%) 0.4
T18 1958-2006 Sentence denotes  50– 10,008 (22.4%) 130 (12.7%) 9878 (22.6%) 1.3
T19 2007-2053 Sentence denotes  60– 8583 (19.2%) 309 (30.2%) 8274 (19.0%) 3.6
T20 2054-2098 Sentence denotes  70– 3918 (8.8%) 312 (30.5%) 3606 (8.3%) 8.0
T21 2099-2145 Sentence denotes  ≥ 80 1408 (3.2%) 208 (20.3%) 1200 (2.7%) 14.8
T22 2146-2162 Sentence denotes Severity*, n (%)
T23 2163-2211 Sentence denotes  Mild/moderate 36,160 (80.9%) 0 36,160 (82.8%) 0
T24 2212-2249 Sentence denotes  Severe 6168 (13.8%) 0 6168 (14.1%) 0
T25 2250-2300 Sentence denotes  Critical 2087 (4.7%) 1023 (100%) 1064 (2.4%) 49.0
T26 2301-2314 Sentence denotes Gender, n (%)
T27 2315-2391 Sentence denotes  Male 22,981 (51.4%) 653 (63.8%) 22,328 (51.2%) 2.8 1.67 (1.47–1.89) < 0.001
T28 2392-2445 Sentence denotes  Female 21,691 (48.6%) 370 (36.2%) 21,321 (48.8%) 1.7
T29 2446-2465 Sentence denotes Comorbidity#, n (%)
T30 2466-2546 Sentence denotes  Hypertension 2683 (12.8%) 161 (39.7%) 2522 (12.3%) 6.0 4.48 (3.69–5.45) < 0.001
T31 2547-2620 Sentence denotes  Diabetes 1102 (5.3%) 80 (19.7%) 1022 (5.0%) 7.3 4.47 (3.49–5.61) < 0.001
T32 2621-2707 Sentence denotes  Cardiovascular disease 873 (4.2%) 92 (22.7%) 781 (3.8%) 10.5 6.75 (5.40–8.43) < 0.001
T33 2708-2789 Sentence denotes  Respiratory disease 511 (2.4%) 32 (7.9%) 479 (2.3%) 6.3 3.43 (2.42–4.87) < 0.001
T34 2790-2855 Sentence denotes  Cancer 107 (0.5%) 6 (1.5%) 101 (0.5%) 5.6 2.93 (1.34–6.41) 0.006
T35 2856-2898 Sentence denotes *Missing data (n = 257 in survivors group)
T36 2899-2984 Sentence denotes #Missing data (n = 617 in the non-survivors group, n = 23,073 in the survivors group)
T37 2985-3058 Sentence denotes Fig. 1 Fatality rate distribution of age (a) and gender (b). ***p < 0.001
T38 3059-3244 Sentence denotes In summary, we found that there was no difference in the prevalence of COVID-19 between men and women, but male patients had a nearly 1.7-fold higher risk of death than female patients.
T39 3245-3337 Sentence denotes Moreover, we concluded that patients with comorbidities had a significantly high death risk.
T40 3338-3539 Sentence denotes Admittedly, due to the unavailability of individual patient data, we could not exclude the influence of age on the conclusion because old patients were more likely to have the underlying comorbidities.
T41 3540-3708 Sentence denotes We would like to provide a reminder to the physicians that more intensive surveillance or treatment should be considered for male patients and those with comorbidities.
T42 3709-3772 Sentence denotes Further and larger studies are needed to validate the findings.
T43 3774-3790 Sentence denotes Publisher’s Note
T44 3791-3909 Sentence denotes Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
T45 3911-3927 Sentence denotes Acknowledgements
T46 3928-3933 Sentence denotes None.
T47 3935-3957 Sentence denotes Authors’ contributions
T48 3958-4015 Sentence denotes GD and FZ conceptualized the idea and designed the study.
T49 4016-4049 Sentence denotes MY and XC revised the manuscript.
T50 4050-4101 Sentence denotes The authors read and approved the final manuscript.
T51 4103-4110 Sentence denotes Funding
T52 4111-4207 Sentence denotes This work was supported by the grants from the National Natural Science Foundation of China (No.
T53 4208-4221 Sentence denotes 81620108024).
T54 4223-4257 Sentence denotes Availability of data and materials
T55 4258-4273 Sentence denotes Not applicable.
T56 4275-4317 Sentence denotes Ethics approval and consent to participate
T57 4318-4333 Sentence denotes Not applicable.
T58 4335-4358 Sentence denotes Consent for publication
T59 4359-4374 Sentence denotes Not applicable.
T60 4376-4395 Sentence denotes Competing interests
T61 4396-4439 Sentence denotes All authors declare no competing interests.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 1208-1230 Phenotype denotes cardiovascular disease http://purl.obolibrary.org/obo/HP_0001626
T2 1274-1286 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T3 2467-2479 Phenotype denotes Hypertension http://purl.obolibrary.org/obo/HP_0000822
T4 2622-2644 Phenotype denotes Cardiovascular disease http://purl.obolibrary.org/obo/HP_0001626
T5 2791-2797 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T1 59-67 SP_7 denotes COVID-19
T2 126-131 GO:0016265 denotes death
T3 135-143 SP_7 denotes COVID-19
T4 345-352 GO:0065007 denotes control
T5 497-502 GO:0016265 denotes death
T6 571-579 SP_7 denotes COVID-19
T7 672-682 SP_7 denotes SARS-CoV-2
T8 910-918 SP_7 denotes COVID-19
T9 1208-1222 UBERON:0004535 denotes cardiovascular
T10 1382-1393 UBERON:0001004 denotes respiratory
T11 1552-1560 SP_7 denotes COVID-19
T12 1627-1657 SP_7 denotes COVID-19 Characteristics Total
T13 2622-2636 UBERON:0004535 denotes Cardiovascular
T15 3130-3138 SP_7 denotes COVID-19
T16 3217-3222 GO:0016265 denotes death
T17 3326-3331 GO:0016265 denotes death
T18 3614-3626 GO:0065007 denotes surveillance
T51280 59-67 SP_7 denotes COVID-19
T14874 126-131 GO:0016265 denotes death
T65338 135-143 SP_7 denotes COVID-19
T80647 345-352 GO:0065007 denotes control
T90898 497-502 GO:0016265 denotes death
T89898 571-579 SP_7 denotes COVID-19
T58247 672-682 SP_7 denotes SARS-CoV-2
T56005 910-918 SP_7 denotes COVID-19
T25359 1208-1222 UBERON:0004535 denotes cardiovascular
T45386 1382-1393 UBERON:0001004 denotes respiratory
T24778 1552-1560 SP_7 denotes COVID-19
T56769 1627-1657 SP_7 denotes COVID-19 Characteristics Total
T38161 2622-2636 UBERON:0004535 denotes Cardiovascular
T89260 3130-3138 SP_7 denotes COVID-19
T78176 3217-3222 GO:0016265 denotes death
T31503 3326-3331 GO:0016265 denotes death
T26047 3614-3626 GO:0065007 denotes surveillance

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2 45-53 Species denotes patients Tax:9606
3 59-67 Disease denotes COVID-19 MESH:C000657245
8 144-152 Species denotes patients Tax:9606
9 126-131 Disease denotes death MESH:D003643
10 135-143 Disease denotes COVID-19 MESH:C000657245
11 497-502 Disease denotes death MESH:D003643
17 2467-2479 Disease denotes Hypertension MESH:D006973
18 2548-2556 Disease denotes Diabetes MESH:D003920
19 2622-2644 Disease denotes Cardiovascular disease MESH:D002318
20 2709-2728 Disease denotes Respiratory disease MESH:D012140
21 2791-2797 Disease denotes Cancer MESH:D009369
23 1627-1635 Disease denotes COVID-19 MESH:C000657245
41 631-639 Species denotes patients Tax:9606
42 706-714 Species denotes patients Tax:9606
43 844-852 Species denotes patients Tax:9606
44 927-930 Species denotes men Tax:9606
45 935-940 Species denotes women Tax:9606
46 1075-1083 Species denotes patients Tax:9606
47 1129-1137 Species denotes patients Tax:9606
48 1538-1546 Species denotes patients Tax:9606
49 571-579 Disease denotes COVID-19 MESH:C000657245
50 672-692 Disease denotes SARS-CoV-2 infection MESH:C000657245
51 910-918 Disease denotes COVID-19 MESH:C000657245
52 1208-1230 Disease denotes cardiovascular disease MESH:D002318
53 1274-1286 Disease denotes hypertension MESH:D006973
54 1330-1338 Disease denotes diabetes MESH:D003920
55 1382-1401 Disease denotes respiratory disease MESH:D012140
56 1449-1456 Disease denotes cancers MESH:D009369
57 1552-1560 Disease denotes COVID-19 MESH:C000657245
69 3147-3150 Species denotes men Tax:9606
70 3155-3160 Species denotes women Tax:9606
71 3171-3179 Species denotes patients Tax:9606
72 3235-3243 Species denotes patients Tax:9606
73 3273-3281 Species denotes patients Tax:9606
74 3390-3397 Species denotes patient Tax:9606
75 3476-3484 Species denotes patients Tax:9606
76 3670-3678 Species denotes patients Tax:9606
77 3130-3138 Disease denotes COVID-19 MESH:C000657245
78 3217-3222 Disease denotes death MESH:D003643
79 3326-3331 Disease denotes death MESH:D003643
81 3958-3960 Disease denotes GD MESH:D005776